Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCB-2019 + CpG 1018 + alum
- Development stage
- Unknown
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SCB-2019 + CpG 1018 + alum is a protein subunit COVID-19 vaccine candidate that combines three components: - **SCB-2019**: A recombinant SARS-CoV-2 spike (S) protein trimer fusion protein preserved in the native trimeric prefusion conformation using Trimer-Tag technology - **CpG 1018**: A toll-like receptor 9 (TLR9) agonist adjuvant developed by Dynavax - **Alum**: Aluminum hydroxide adjuvant Each dose contains 30 μg of SCB-2019 antigen, 1.5 mg of CpG 1018, and 0.75 mg of aluminum hydroxide, administered as a 0.5 mL intramuscular injection. The vaccine is given as a two-dose regimen with doses administered 21 days apart. Phase 2/3 clinical trials involving over 30,000 participants across five countries demonstrated 100% efficacy against severe COVID-19 and hospitalization. The vaccine can be stored under standard refrigeration conditions (2-8°C).
- Other names
- S-Trimer + alum adjuvantTrimeric Recombinant protein-based COVID-19 vaccine adjuvanted with alumSCB-2019 (CpG 1018/alum)
02
Targets
SARS-CoV-2 spikeTLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on SCB-2019 + CpG 1018 + alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCB-2019 + CpG 1018 + alum.